FUSN Stock Overview
A clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Fusion Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.55 |
| 52 Week High | US$21.60 |
| 52 Week Low | US$2.31 |
| Beta | -0.69 |
| 11 Month Change | 0.70% |
| 3 Month Change | 114.64% |
| 1 Year Change | 332.73% |
| 33 Year Change | 150.29% |
| 5 Year Change | n/a |
| Change since IPO | 26.76% |
Recent News & Updates
Recent updates
Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook
Mar 03Health Check: How Prudently Does Fusion Pharmaceuticals (NASDAQ:FUSN) Use Debt?
Jan 30
Fusion Pharmaceuticals initiated at buy at Truist on lead candidate for solid tumors
Sep 16Fusion Pharma doses first patient in phase 1/2 study for solid tumors treatment
Aug 29Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?
Aug 10Fusion Pharmaceuticals GAAP EPS of -$0.44 beats by $0.09, revenue of $0.57M beats by $0.46M
Aug 09Fusion Pharma wins FDA nod to start trials for solid tumor candidate
Jun 23We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate
Jan 16We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate
Aug 28Fusion Pharma trades higher on early-stage data for cancer therapy
Jun 14We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely
Apr 05How Much Of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Do Institutions Own?
Mar 01Who Has Been Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Shares?
Jan 25Here's Why We're Not Too Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Situation
Dec 21Fusion Pharmaceuticals EPS misses by $0.04
Nov 10Fusion Pharma teams up with AstraZeneca in next-gen radiopharmaceuticals for cancer
Nov 02Shareholder Returns
| FUSN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.4% | 2.4% | 2.2% |
| 1Y | 332.7% | 16.2% | 31.7% |
Return vs Industry: FUSN exceeded the US Biotechs industry which returned 6.7% over the past year.
Return vs Market: FUSN exceeded the US Market which returned 21.7% over the past year.
Price Volatility
| FUSN volatility | |
|---|---|
| FUSN Average Weekly Movement | 28.5% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: FUSN's share price has been volatile over the past 3 months.
Volatility Over Time: FUSN's weekly volatility has increased from 18% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 101 | John Valliant | www.fusionpharma.com |
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company’s lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations.
Fusion Pharmaceuticals Inc. Fundamentals Summary
| FUSN fundamental statistics | |
|---|---|
| Market cap | US$1.83b |
| Earnings (TTM) | -US$104.28m |
| Revenue (TTM) | US$2.04m |
898.6x
P/S Ratio-17.6x
P/E RatioIs FUSN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FUSN income statement (TTM) | |
|---|---|
| Revenue | US$2.04m |
| Cost of Revenue | US$75.54m |
| Gross Profit | -US$73.50m |
| Other Expenses | US$30.78m |
| Earnings | -US$104.28m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.23 |
| Gross Margin | -3,602.84% |
| Net Profit Margin | -5,111.57% |
| Debt/Equity Ratio | 20.5% |
How did FUSN perform over the long term?
See historical performance and comparison